Breast cancer is a common cancer that encompasses multiple subtypes, and treatment decisions are often guided by the presence or absence of hormone receptors (ER, PR) and HER2 [(Orrantia-Borunda et al., 2022; Turner et al., 2021)]. Here, ERBB2 is linked to breast carcinoma.